

20/576175

CASE 33440-US-PCT

AP20 Res'd PCT/PTO 19 APR 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

GRAEME BILBE

INTERNATIONAL APPLICATION NO: PCT/EP2004/012080

FILED: 26 OCTOBER 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: USE OF PYRIDINYL-PYRIMIDINYLAMINO-BENZAMIDE
DERIVATIVES FOR THE TREATMENT OF AMYLOID RELATED
DISORDERS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed. Also enclosed is a copy of a British Search Report.

10/576175

AP20 Rec'd PCT/PTO 19 APR 2006

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: *April 19, 2006*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT
Graeme BILBE

FILING DATE
Here with

AP20050101 PTO 19 APR 2006 Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	*03 057165	7/17/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	*03 004488	1/16/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	*2004/029038	4/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	*0 588 762	3/23/94	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	*2004/005281	1/15/04	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	*Zimmermann et al., "Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives," Bioorganic & Medicinal Chemistry Letters, Oxford, GB, Vol. 7(2), pp. 187-192 (1997)
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33440-USPTO
APPLICATION NO.
Not Yet Known
APPLICANT
Graeme BILBE
FILING DATE
Herewith

80/576175

AP20 Rev 3/2006 19 APR 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	95 09853	4/13/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.